Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance

IRADIMED CORP

2026-Q1 EPS reported $0.45 revenue$21,979,000

Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).
Declares regular quarterly dividend $0.20/share, payable May 29, 2026 to holders of record May 15, 2026.
Reaffirms FY 2026 guidance: revenue $91M-$96M; GAAP EPS $1.90-$2.05; non-GAAP EPS $2.06-$2.21.
Launched next-gen 3870 MRI-compatible IV infusion pump; early orders strong; Q2 shipments expected.
Operating cash flow $8.3M, up 93% YoY; gross margin improved to 77% from 76%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

IRADIMED CORP reported first quarter of 2026 results: revenue revenue of $22.0 million, net income net income of $5.8 million, EPS $0.45 per diluted share. Guidance reaffirmed.

Period: first quarter of 2026
Revenue: revenue of $22.0 million
Net income: net income of $5.8 million
EPS: $0.45 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

IRADIMED CORPORATION Reports First Quarter 2026 Financial Results Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance • Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. • Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

IRADIMED CORP filing history →

Source: SEC EDGAR

accession 0001628280-26-029125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.